A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. - Wikidata - awgldk - TriplyDB

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

http://www.wikidata.org/entity/Q35162749

about

Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease Treatment for familial amyotrophic lateral sclerosis/motor neuron disease Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice Mechanisms underlying inflammation in neurodegeneration Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures Progressive Staging of Pilot Studies to Improve Phase III Trials for Motor Interventions.Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research.Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition.New considerations in the design of clinical trials for amyotrophic lateral sclerosis A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.Advances in designs for Alzheimer's disease clinical trials.A pilot open-label trial of minocycline in patients with autism and regressive features High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial Toward more efficient clinical trials for amyotrophic lateral sclerosis.Creatine in mouse models of neurodegeneration and aging.Emerging drugs for amyotrophic lateral sclerosis.How can we improve clinical trials in amyotrophic lateral sclerosis?Disease modification in epilepsy: from animal models to clinical applications.Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy.A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.Right job, wrong tool: a commentary on designing clinical trials for Ebola virus disease.Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials.Current and emerging treatments for amyotrophic lateral sclerosis.Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS.Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models.Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis.Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis.Response to commentary on a novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS

P2860

Q24200285-DFC10679-E0C5-456E-AFE2-CADA5ED2AADE Q24241570-0F188E83-C652-4EB0-92FB-E7EA1E46C2FC Q26823418-4DFCF396-0762-4BD6-90B6-A072BE9369BE Q27021917-9B90D266-6964-489C-AF10-EA20B70B7244 Q28484151-7A90B064-6230-4AB9-9706-D5E8B6EB7071 Q28533705-B0D70B50-A369-4D54-9B35-E1A8179AEDEF Q29617977-98F5362F-6EFD-40EF-A6DE-B92A6E614828 Q33650170-0E8498B3-DF92-44C7-BDC1-B90A32E4650F Q33904274-EE537F8D-2DEC-4C6B-8F09-A1AC28540575 Q33985590-48AE28FB-FCE1-41A1-943F-892FD0F17BFE Q34401653-927C335A-FC61-4423-90D6-34654170058B Q35116500-4E7C9365-2E52-4E84-BC2E-AC25DDA28007 Q35910744-A99F1402-DA87-4BCD-8F85-B5522B26DFEF Q36177001-FAF90B34-4DC4-40E9-9129-70DB00F29C36 Q36202825-F38A7442-1AC3-4D79-9A79-CD111AC8B9AD Q36576472-65859488-6011-4DFF-A2E8-7C2571A2C9E1 Q36874302-6639605D-8E77-48D6-AFDE-BAFA17B7A4D3 Q37118241-308C31E0-42B1-4535-B542-7688EC60260D Q37644480-FF19E291-D907-486B-8678-2FB8FEC03520 Q37851389-9397AB6A-DD32-4F0F-9BC5-806E92099129 Q37909351-6C169AAD-B678-4423-B45D-AFBC4F77AF41 Q37938694-2CEFFA4B-9B3C-4560-B7DB-CC2BEE90E6FC Q38450069-BC9CC4EA-CE1D-4C4B-BECC-691109E250AF Q38542939-EBEB4120-1639-4F3C-A562-838F08462DCB Q38573829-B8193494-3BE7-4FCD-A11D-374C1F8C49CE Q38847200-98DE4824-832F-4FF2-9E18-A22D81E1552B Q39033807-5866517B-6D80-4A18-8CEC-4373D4B83529 Q40161573-DE58A524-FBAA-4C32-951D-42DFF89FFD2E Q42367893-DF2E2382-FF2B-46FD-BBAE-8C34ECA7DF8B Q42685032-A97F7BA7-5431-4414-986F-70DBE5227C21 Q43239617-635860A3-54C5-44D5-85BB-C30187CF6FBE Q44692126-3080C698-7199-4DBD-915B-0D619120CA73 Q48116439-A4B7C8DC-D4E3-4DEC-85B1-E675B459987D Q48547293-AEED21E3-EE76-46FE-AE02-25AD2EFE2786 Q58125397-881DD90B-4BB2-4361-92F2-E8035F8DF55A

P2860

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

http://www.wikidata.org/entity/Q35162749

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

A novel, efficient, randomized ...... tions of drug therapy for ALS.

@ast

A novel, efficient, randomized ...... tions of drug therapy for ALS.

@en

type

label

A novel, efficient, randomized ...... tions of drug therapy for ALS.

@ast

A novel, efficient, randomized ...... tions of drug therapy for ALS.

@en

prefLabel

A novel, efficient, randomized ...... tions of drug therapy for ALS.

@ast

A novel, efficient, randomized ...... tions of drug therapy for ALS.

@en

P1433

Q35162749-237FFE1C-0415-4E4C-A1E3-9C7C3F9F002E

P1476

Q35162749-D19C614D-64F0-441A-8B79-20E40D8128D3

P2093

Q35162749-0AABDC17-0782-40F2-A8AA-88D97D862299

Q35162749-1457E222-6DEF-4F75-8D95-447352B22868

Q35162749-22853999-B174-4CCF-8B26-E8136C17A57E

Q35162749-252271C7-7314-40F4-BE98-0153A65E7771

Q35162749-274E8CCC-B3DE-4E8F-9225-D68CED4860C8

Q35162749-2BF5D660-A43A-49D6-B6D8-241E96B7ACA4

Q35162749-3F3B3545-BBED-4A50-AD85-10DFA3056B26

Q35162749-40108BB1-8084-4018-A53A-F13781BE3306

Q35162749-566F6867-A92A-45AC-86D6-43389A5DD8E0

Q35162749-6768BB82-14B2-4052-80BF-31E71DADE106

P2860

Q35162749-05050D71-5B8C-455E-88E2-2BA958DE9811

Q35162749-25125E8B-8B93-436C-A391-2C1ABF4AAFC6

Q35162749-277FF833-9171-49C2-8834-87FAF703C8AA

Q35162749-440C9F18-5164-4688-9E88-CD4163BC2F2E

Q35162749-4B66D847-EE2A-4114-A371-B1F3A14EE986

Q35162749-4BC9BB46-99DC-4565-9082-2A7546EA65F3

Q35162749-4D1407B5-0FB0-4829-9637-F78E621A29BF

Q35162749-579017F8-FF2A-4B02-B563-CAE9663BA8A2

Q35162749-5F1E8AC8-B3B4-420F-970C-4D233CD29297

Q35162749-706B91F8-5277-4917-B6BE-1BB442D59DA3

P304

Q35162749-1654BB11-3BE8-47A9-8B89-A1BCA1E69762

P31

Q35162749-E69C5AB6-AE66-4C65-993C-A508E4CFC616

P356

Q35162749-EAAAFD18-C00C-4C53-91C6-B697353ADA2C

P433

Q35162749-4C89E8E0-4984-4F2D-A80C-C1033821F2EA

P478

Q35162749-ACB637CE-7427-4A6E-AC94-69933C19C40A

P50

Q35162749-9B691417-9002-4A42-AB68-861342F2C6CB

P577

Q35162749-AD2AD63D-DFBA-47EE-85DD-64E42B54D3EB

P698

Q35162749-9C7FEF08-F4B4-4B25-8411-FF5806E40EA0

P921

Q35162749-CEDBB86E-B30C-4BF0-8238-31E4456BB338

P932

Q35162749-0BE2CE09-104F-4206-BAD3-247041A767A5

P356

17482960802195632

P1433

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

P1476

A novel, efficient, randomized ...... tions of drug therapy for ALS.

@en

P2093

Alan Pestronk

http://www.w3.org/2001/XMLSchema#string

Bruce Levin

http://www.w3.org/2001/XMLSchema#string

Carolyn Doorish

http://www.w3.org/2001/XMLSchema#string

Combination Drug Selection Trial Study Group

http://www.w3.org/2001/XMLSchema#string

David Saperstein

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Kelvin

http://www.w3.org/2001/XMLSchema#string

Eric J Sorenson

http://www.w3.org/2001/XMLSchema#string

Howard Andrews

http://www.w3.org/2001/XMLSchema#string

Jacqueline Montes

http://www.w3.org/2001/XMLSchema#string

Jau-Shin Lou

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II/III randomized trial of TCH346 in patients with ALS

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis

Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia.

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials.

Mitochondrial involvement in amyotrophic lateral sclerosis.

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders.

Selecting promising ALS therapies in clinical trials.

P304

212-222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17482960802195632

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Hiroshi Mitsumoto

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18608093

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

P932

4354803

http://www.w3.org/2001/XMLSchema#string